TY - JOUR
T1 - Prevalence of HIV, HCV and HBV in Central Asia and the Caucasus
T2 - A systematic review
AU - Davlidova, Salima
AU - Haley-Johnson, Zoë
AU - Nyhan, Kate
AU - Farooq, Ayesha
AU - Vermund, Sten H.
AU - Ali, Syed
N1 - Funding Information:
Funded, in part, by National Institutes of Health grants #P30MH062294 (SHV) and #R03DA052179 (SHV and SHA), and by Nazarbayev University #110119FD4516 (SHA).
Publisher Copyright:
© 2020 The Author(s)
Copyright:
Copyright 2021 Elsevier B.V., All rights reserved.
PY - 2021/3
Y1 - 2021/3
N2 - Background: Human immunodeficiency virus (HIV), hepatitis C virus (HCV) and hepatitis B virus (HBV) are substantial public health threats in the region of Central Asia and the Caucasus, where the prevalence of these infections is currently rising. Methods: A systematic review of MEDLINE, Embase and PsycINFO was conducted with no publication date or language restrictions through October 2019. Additional data were also harvested from national surveillance reports, references found in discovered sources, and other “grey” literature. It included studies conducted on high-risk populations (people who inject drugs (PWID), female sex workers (FSW), men who have sex with men (MSM), prisoners, and migrants) in Central Asia: Kazakhstan, Kyrgyzstan, Tajikistan, Turkmenistan, and Uzbekistan; and the Caucasus: Armenia, Azerbaijan, Georgia, and Northern Caucasus region of the Russian Federation. Results: Wide ranges were noted for HIV prevalence: PWID 0–30.1%, MSM 0–25.1%, prisoners 0–22.8%, FSW 0–10.0%, and migrants 0.06–1.5%, with the highest prevalence of these high-risk groups reported in Kazakhstan (for PWID), Georgia (for MSM and prisoners) and Uzbekistan (for migrants). HCV prevalence also had a wide range: PWID 0.3–92.1%, MSM 0–18.9%, prisoners 23.8–49.7%, FSW 3.3–17.8%, and migrants 0.5–26.5%, with the highest prevalence reported in Georgia (92.1%), Kyrgyzstan (49.7%), and migrants from Tajikistan and Uzbekistan (26.5%). Similarly, HBV prevalence had a wide range: PWID 2.8–79.7%, MSM 0–22.2%, prisoners 2.7–6.2%, FSW 18.4% (one study), and migrants 0.3–15.7%. Conclusion: In Central Asia and the Caucasus, prevalence of HIV, HCV and HBV remains exceedingly high among selected populations, notably PWID and MSM.
AB - Background: Human immunodeficiency virus (HIV), hepatitis C virus (HCV) and hepatitis B virus (HBV) are substantial public health threats in the region of Central Asia and the Caucasus, where the prevalence of these infections is currently rising. Methods: A systematic review of MEDLINE, Embase and PsycINFO was conducted with no publication date or language restrictions through October 2019. Additional data were also harvested from national surveillance reports, references found in discovered sources, and other “grey” literature. It included studies conducted on high-risk populations (people who inject drugs (PWID), female sex workers (FSW), men who have sex with men (MSM), prisoners, and migrants) in Central Asia: Kazakhstan, Kyrgyzstan, Tajikistan, Turkmenistan, and Uzbekistan; and the Caucasus: Armenia, Azerbaijan, Georgia, and Northern Caucasus region of the Russian Federation. Results: Wide ranges were noted for HIV prevalence: PWID 0–30.1%, MSM 0–25.1%, prisoners 0–22.8%, FSW 0–10.0%, and migrants 0.06–1.5%, with the highest prevalence of these high-risk groups reported in Kazakhstan (for PWID), Georgia (for MSM and prisoners) and Uzbekistan (for migrants). HCV prevalence also had a wide range: PWID 0.3–92.1%, MSM 0–18.9%, prisoners 23.8–49.7%, FSW 3.3–17.8%, and migrants 0.5–26.5%, with the highest prevalence reported in Georgia (92.1%), Kyrgyzstan (49.7%), and migrants from Tajikistan and Uzbekistan (26.5%). Similarly, HBV prevalence had a wide range: PWID 2.8–79.7%, MSM 0–22.2%, prisoners 2.7–6.2%, FSW 18.4% (one study), and migrants 0.3–15.7%. Conclusion: In Central Asia and the Caucasus, prevalence of HIV, HCV and HBV remains exceedingly high among selected populations, notably PWID and MSM.
KW - Caucasus
KW - Central Asia
KW - Hepatitis B virus
KW - Hepatitis C virus
KW - Human immunodeficiency virus
UR - http://www.scopus.com/inward/record.url?scp=85100506946&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85100506946&partnerID=8YFLogxK
U2 - 10.1016/j.ijid.2020.12.068
DO - 10.1016/j.ijid.2020.12.068
M3 - Review article
C2 - 33385583
AN - SCOPUS:85100506946
VL - 104
SP - 510
EP - 525
JO - International Journal of Infectious Diseases
JF - International Journal of Infectious Diseases
SN - 1201-9712
ER -